0001140361-17-016029.txt : 20170417 0001140361-17-016029.hdr.sgml : 20170417 20170417182521 ACCESSION NUMBER: 0001140361-17-016029 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170414 FILED AS OF DATE: 20170417 DATE AS OF CHANGE: 20170417 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kavanaugh William Michael CENTRAL INDEX KEY: 0001578767 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 17765571 MAIL ADDRESS: STREET 1: C/O FIVE PRIME THERAPEUTICS, INC. STREET 2: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2017-04-14 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001578767 Kavanaugh William Michael 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 CSO, Head Res.&Non-Clin. Dev. Stock Option (Right to Buy) 4.4728 2017-04-14 4 A 0 48368 0.00 A 2025-05-06 Common Stock 48368 96736 D On May 7, 2015, the Reporting Person was granted an option to purchase 96,736 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On September 26, 2016, the first performance milestone was achieved resulting in 50% of the Performance Option vesting. On April 14, 2017, the second performance milestone was achieved resulting in the remaining 50% of the Performance Option vesting. /s/ Cynthia J. Ladd, as Attorney-in-Fact for Michael Kavanaugh 2017-04-17